Literature DB >> 16434715

Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries.

Susan K Hollingshead1, Laurence Baril2,3, Santiago Ferro4, Janice King1, Pat Coan1, David E Briles1.   

Abstract

The pneumococcal surface protein PspA, a cell-wall-associated surface protein, is a promising component for pneumococcal vaccines. In this study, the distribution of the PspA family was determined in a panel of invasive and clinically important pneumococcal isolates from adults over 50 years of age, collected between 1995 and 2002. One thousand eight hundred and forty-seven recent isolates from invasive pneumococcal disease were obtained from seven Western countries, together with clinical data. An ELISA-based serological method was standardized in order to determine the PspA family and clade distribution. Molecular tests were used when isolates were non-typable by ELISA (PspA family typing by PCR). Only 42 (2.3 %) isolates were non-typable by ELISA and PspA family typing by PCR was performed. Finally, 3 isolates were considered as non-pneumococcal and 1844 were classified as follows: 749 (40.6 %) were PspA family 1, 1078 (58.5 %) were PspA family 2, 13 (0.7 %) were PspA family 1 and 2 and 4 (0.2 %) remained non-typable. The cross-reactivity of antibodies to PspAs of different clades was confirmed. In conclusion, inclusion of PspA family 1 and family 2 in future pneumococcal vaccines would ensure broad coverage of pneumococcal strains infecting people over 50 years of age.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434715     DOI: 10.1099/jmm.0.46268-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  43 in total

1.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  Christina M Croney; Mamie T Coats; Moon H Nahm; David E Briles; Marilyn J Crain
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

3.  Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults.

Authors:  L Baril; J Dietemann; M Essevaz-Roulet; L Béniguel; P Coan; D E Briles; B Guy; G Cozon
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

4.  Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil.

Authors:  Fabiana Cristina Pimenta; Fátima Ribeiro-Dias; Maria Cristina C Brandileone; Eliane N Miyaji; Luciana C C Leite; Ana Lúcia S Sgambatti de Andrade
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

6.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

7.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

8.  Identification of glycosylated regions in pneumococcal PspA conjugated to serotype 6B capsular polysaccharide.

Authors:  Giovana Cappio Barazzone; Vittoria Pinto; Danilo Donnarumma; Martha Massako Tanizaki; Nathalie Norais; Francesco Berti
Journal:  Glycoconj J       Date:  2014-04       Impact factor: 2.916

9.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

10.  Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B.

Authors:  Merit Melin; Hanna Jarva; Lotta Siira; Seppo Meri; Helena Käyhty; Merja Väkeväinen
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.